首页|中性粒细胞与淋巴细胞比值对单药免疫治疗非小细胞肺癌患者预后的预测价值分析

中性粒细胞与淋巴细胞比值对单药免疫治疗非小细胞肺癌患者预后的预测价值分析

扫码查看
目的 探讨中性粒细胞与淋巴细胞比值(NLR)对接受单药免疫治疗非小细胞肺癌(NSCLC)患者无进展生存期(PFS)的预测价值.方法 回顾性分析接受单药免疫治疗的 30 例NSCLC患者的临床资料,收集免疫治疗前的NLR、血小板与淋巴细胞比值(PLR),应用Kaplan-Meier方法进行生存分析,探讨接受单药免疫治疗NSCLC患者PFS的影响因素.结果 按NLR的中位数 3.30 将患者分为高NLR组(n=15)和低NLR组(n=15);按PLR的中位数 178.11 将患者分为高PLR组(n=15)和低PLR组(n=15),所有患者中位PFS为 2.9 个月.Kaplan-Meier生存分析显示,低NLR组的中位PFS为 3.9 个月[95%CI=(2.006,5.794)],明显长于高NLR组的 2.8 个月[95%CI=(2.552,3.048)],经过Log-rank检验得出P=0.002<0.05;高PLR组的中位PFS为 2.7 个月[95%CI=(2.416,2.984)],显著短于低PLR组的3.8 个月[95%CI=(3.043,4.557)],经过Log-rank检验得出P=0.03<0.05.单因素分析结果显示:性别、NLR、PLR是PFS的影响因素(P<0.05);经过COX多元回归模型校对性别因素后,多因素分析结果显示:NLR是接受单药免疫治疗NSCLC患者PFS的影响因素(P=0.001<0.05);PLR不是接受单药免疫治疗NSCLC患者PFS的影响因素(P>0.05).结论 在接受免疫单药治疗的NSCLC患者中,较低水平的NLR患者的PFS更长,对其预后有一定的预测作用.
Analysis of prognostic value of neutrophil to lymphocyte ratio in patients with non-small cell lung cancer treated with single-agent immunotherapy
Objective To investigate the prognostic effects of neutrophil to lymphocyte ratio(NLR)on progression free survival(PFS)in patients with non-small cell lung cancer(NSCLC)receiving single-agent immunotherapy.Methods Retrospective analysis was made on 30 patients with NSCLC who received single-agent immunotherapy.NLR and platelet to lymphocyte ratio(PLR)before immunotherapy was collected,and Kaplan-Meier method was used for survival analysis to explore the factors affecting PFS.Results Patients were divided into high NLR group(n=15)and low NLR group(n=15)according to the median NLR of 3.30.Patients were divided into high PLR(n=15)and low PLR(n=15)groups based on a median PLR of 178.11,with a median PFS of 2.9 months for all patients.Kaplan-Meier survival analysis showed that the median PFS in the low NLR group was 3.9 months[95%CI=(2.006,5.794)],which was significantly longer than 2.8 months[95%CI=(2.552,3.048)]in the high NLR group,with a Log-rank test yielding P=0.002<0.05.The median PFS in the high PLR group was 2.7 months[95%CI=(2.416,2.984)],which was significantly shorter than 3.8 months[95%CI=(3.043,4.557)]in the low PLR group,with a Log-rank test yielding P=0.03<0.05.Univariate analysis showed that gender,NLR and PLR were the influencing factors of PFS(P<0.05).After checking gender factors by COX multiple regression model,the results of multivariate analysis showed that NLR was the influential factor for PFS in NSCLC patients receiving monotherapy(P=0.001<0.05).PLR was not an influential factor for PFS in NSCLC patients receiving single-agent immunotherapy(P>0.05).Conclusion In NSCLC patients receiving single-agent immunotherapy,the PFS of patients with lower levels of NLR is longer,which can predict the prognosis of NSCLC patients receiving immunomonotherapy.

Neutrophil to lymphocyte ratioPlatelet to lymphocyte ratioNon-small cell lung cancerSingle-agent immunotherapyProgression-free survivalPredictive value

秦垠、张永华、钱伟华、潘迎英、沈政洁、刘莲芳

展开 >

215600 张家港市中医医院肿瘤血液科

中性粒细胞与淋巴细胞比值 血小板与淋巴细胞比值 非小细胞肺癌 单药免疫治疗 无进展生存期 预测价值

2020年张家港市中医医院青年自然科学基金2020年苏州市重点病种项目2022年南京中医药大学自然科学基金

ZZYQ2012LCZX202018XZR2021055

2024

中国实用医药
中国康复医学会

中国实用医药

影响因子:0.797
ISSN:1673-7555
年,卷(期):2024.19(4)
  • 16